SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): FEBRUARY 27, 1998
IVAX CORPORATION
4400 BISCAYNE BOULEVARD, MIAMI, FLORIDA 33137
305-575-6000
<TABLE>
<S> <C> <C>
Incorporated under the laws of the Commission File Number I.R.S. Employer Identification Number
STATE OF FLORIDA 1-09623 16-1003559
</TABLE>
<PAGE>
ITEM 5. OTHER EVENTS.
On February 27, 1998, IVAX Corporation issued a press release
announcing that its 1998 annual meeting of shareholders will be held on June 5,
1998 and that any shareholder proposals intended to be presented at the meeting
must be received by IVAX no later than April 1, 1998. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K and
incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 Press Release of IVAX Corporation dated February 27,
1998.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IVAX CORPORATION
\S\ ARMANDO A. TABERNILLA
-------------------------
Armando A. Tabernilla
Senior Vice President and General Counsel
Date: February 27, 1998
-2-
<PAGE>
EXHIBIT INDEX
Exhibit Description
- ------- -----------
99.1 Press Release of IVAX Corporation dated February 27, 1998
EXHIBIT 99.1
IVAX ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS
MIAMI, February 27, 1998 -- IVAX Corporation (AMEX:IVX) today announced
that its annual shareholders meeting will be held on June 5, 1998. Any
shareholder proposals intended to be presented at the meeting must be received
by the company's secretary no later than April 1, 1998 in order to be considered
for inclusion in IVAX's proxy statement in connection with its annual meeting.
IVAX Corporation, headquartered in Miami Florida, is a holding company
with core subsidiaries engaged in the research, development, manufacture and
marketing generic and branded pharmaceuticals.
CONTACT:
Robert Jaffe
Director,
Corporate Communications
IVAX Corporation
305-575-6041
